Welcome to our dedicated page for Proqr Therapeuti SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProQR Therapeutics N.V. (Nasdaq: PRQR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. ProQR files annual reports on Form 20-F and periodic current reports on Form 6-K, which include press releases, unaudited financial statements, and materials from analyst and investor events. These filings document the evolution of ProQR’s Axiomer RNA editing platform, its clinical and preclinical pipeline, and its financial position over time.
Recent Form 6-K filings referenced by ProQR furnish unaudited financial statements for quarterly periods and press releases such as “ProQR Announces Third Quarter 2025 Operating and Financial Results” and “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” Other 6-Ks include materials from a virtual analyst and investor event focused on the AX-0810 Phase 1 trial design and biomarker strategy, and announcements related to the submission and authorization of a Clinical Trial Application for AX-0810 targeting NTCP.
For investors analyzing PRQR, these filings provide detail on revenue from collaborations, research and development and general and administrative costs, net loss, cash and cash equivalents, deferred income, and other balance sheet items. They also describe ProQR’s strategic collaboration with Eli Lilly, including milestone income and the framework for potential additional targets. Clinical and pipeline-related disclosures in the filings outline the status of programs such as AX-0810, AX-2402, AX-2911, and AX-1412, along with planned milestones and study objectives.
On Stock Titan, ProQR filings are updated in step with EDGAR so users can review new 6-K submissions and other forms as they appear. AI-powered summaries help explain the key points of lengthy documents, highlight important changes in financials, and clarify technical language around RNA editing, clinical trial design, and collaboration terms. Users can quickly navigate to quarterly reports, annual Form 20-F information, and current reports that capture major business and clinical events, supporting deeper due diligence on PRQR’s regulatory and financial disclosures.
ProQR Therapeutics N.V. provides its Annual Report on Form 20-F for the year ended December 31, 2025, detailing a strategic focus on its Axiomer RNA editing platform. The company reports a net loss of €42.184 million in 2025 and an accumulated deficit of €467.506 million, reflecting continued heavy investment in R&D.
As of December 31, 2025, ProQR held €92.413 million in cash and cash equivalents and estimates this will fund operations into mid‑2027. The report notes that clinical development for legacy ophthalmology programs has ceased or been sold, while a Phase 1 trial of lead candidate AX‑0810 in healthy volunteers began in December 2025 for cholestatic diseases.
Management emphasizes significant ongoing risks typical for early‑stage biotech, including substantial future capital needs, regulatory uncertainty around novel RNA editing technology, reliance on third‑party collaborators and manufacturers, and extensive operational, ESG, geopolitical and intellectual property risks that could materially affect future results.
ProQR Therapeutics N.V. reported full-year 2025 results and a business update centered on its Axiomer RNA editing platform. Lead program AX-0810 for cholestatic diseases is in an ongoing Phase 1 trial, with target engagement data expected in the first half of 2026.
The company advanced its broader pipeline by selecting development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, and earned $4.5 million in milestones from its collaboration with Eli Lilly during 2025. Management highlighted continued execution of the Lilly partnership into 2026.
Financially, ProQR ended 2025 with cash and cash equivalents of approximately €92.4 million, down from €149.4 million a year earlier. Net cash used in operating activities was €52.8 million. Research and development costs were €44.7 million and general and administrative costs were €15.1 million. Net loss for 2025 was €42.2 million, or €0.40 per diluted share.
ProQR Therapeutics reported planned changes to its Board of Directors. Co-founder Dinko Valerio and director Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting as their terms conclude.
The company has engaged an executive search firm to identify new Board candidates to support its long-term strategy, governance and succession planning as it advances clinical programs based on its proprietary Axiomer™ RNA editing technology platform.
ProQR Therapeutics N.V. received an amended Schedule 13D showing that a group of related Dutch investment entities led by Van Herk Investments B.V. beneficially owns 15,384,250 ordinary shares, representing 14.6% of the company’s ordinary shares outstanding as of September 30, 2025.
From October 3, 2025 to February 5, 2026, Van Herk Investments B.V. bought an additional 1,054,560 shares in open-market transactions for a total of $2,154,236.73, funded from its general working capital. The filing states the shares are held for investment, but the reporting persons may engage with ProQR’s management and board, discuss strategy and potential business combinations, propose changes to capitalization or board structure, or buy or sell more shares depending on market and company conditions.
ProQR Therapeutics N.V. received a Schedule 13G filing from several Dutch investment entities and portfolio manager Patrick Johan Hendrik Krol, disclosing passive ownership positions in the company’s ordinary shares.
Aescap Life Sciences reports beneficial ownership of approximately 3.9% of ProQR’s ordinary shares, while Privium Fund Management B.V., as fund manager of Aescap Life Sciences and Aescap Genetics, reports beneficial ownership of about 5.2%. Aescap Genetics holds around 1.2% and Inspirational Visions about 0.1% of the outstanding shares. Krol, through his roles with these entities and his own holdings, may be deemed to beneficially own approximately 5.2% of the shares.
The percentages are based on 105,345,192 ordinary shares outstanding as of September 30, 2025. The filing certifies that the securities were not acquired for the purpose of changing or influencing control of ProQR and are held on a passive basis.
ProQR Therapeutics N.V. submitted a report as a foreign private issuer to make public a new press release titled “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” The press release, attached as an exhibit, highlights early safety and pharmacokinetic results for the AX-0810 program, the selection of development candidates, and the company’s outlook for 2026. ProQR also states that this information is incorporated by reference into several of its existing Form F-3 registration statements.
ProQR Therapeutics N.V. has filed a Form 6-K furnishing unaudited financial statements for the three and nine-month periods ended September 30, 2025, and a related press release. The press release, titled “ProQR Announces Third Quarter 2025 Operating and Financial Results,” also provides a business update.
The information in this report, including the exhibits, is incorporated by reference into ProQR’s existing shelf registration statements on Form F-3. This links the latest quarterly financial and operating information directly to ProQR’s current securities registration framework.
ProQR Therapeutics N.V. filed a Form 6-K noting it hosted a virtual analyst and investor event titled “Entering the Clinic with AX-0810: Establishing Safety, PK, and the Biomarker Roadmap for Proof of Target Engagement.” The session covered its AX-0810 lead program, a strategic overview, and corporate outlook.
The related investor presentation is furnished as Exhibit 99.1. The company states that the information is incorporated by reference into its Form F-3 registration statements (File Nos. 333-282419, 333-270943, 333-263166, and 333-285767).
Van Herk group disclosed ownership of 14,329,690 ordinary shares of ProQR Therapeutics N.V. (PRQR), representing 13.6% of the company based on 105,344,052 shares outstanding as of June 30, 2025. The filing (Amendment No. 3 to a Schedule 13D) reports that Van Herk Investments B.V. purchased 1,055,000 ordinary shares in open-market transactions from September 5, 2025 to September 29, 2025 for an aggregate net amount of $2,300,635.14 using its general working capital. The reporting group is a network of Netherlands entities and related parties coordinated through Adrianus van Herk, and they state the shares were acquired for investment purposes in the ordinary course of business and that they may review or change their position over time, including engaging with management, acquiring or selling shares, or pursuing other strategic actions.
Van Herk group now holds a 12.6% stake in ProQR Therapeutics N.V. The Schedule 13D/A reports that Van Herk Investments B.V. and affiliated entities beneficially own 13,274,690 ordinary shares out of 105,344,052 outstanding shares as of June 30, 2025. From August 20, 2025 to September 3, 2025, Van Herk Investments B.V. purchased 1,072,500 ordinary shares in open market transactions for an aggregate net amount of $2,401,687.56, funded from its general working capital. The filing states the shares were acquired for investment purposes and that the Reporting Persons will continue to review their investment and may, depending on circumstances, communicate with management or the board, make proposals regarding capitalization or board composition, buy or sell shares, or use hedging or derivative transactions.